Zoetis Inc. $ZTS Shares Bought by Horizon Investments LLC

Horizon Investments LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 30.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,539 shares of the company’s stock after buying an additional 4,979 shares during the period. Horizon Investments LLC’s holdings in Zoetis were worth $2,698,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ZTS. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC acquired a new stake in Zoetis in the 4th quarter valued at about $30,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis in the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC bought a new position in shares of Zoetis during the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Zoetis in the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of research reports. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Citigroup started coverage on Zoetis in a research note on Wednesday, April 15th. They set a “buy” rating and a $145.00 price objective for the company. Finally, Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $151.75.

Zoetis Trading Down 1.2%

NYSE ZTS opened at $112.81 on Tuesday. The firm’s 50 day moving average price is $119.93 and its two-hundred day moving average price is $124.53. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a twelve month low of $112.10 and a twelve month high of $172.23. The stock has a market cap of $47.45 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.76 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the prior year, the company earned $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts anticipate that Zoetis Inc. will post 7.01 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.